Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 14/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987258 | 0.98 | GLS (0.70) | GLSALDH1A1CA2HSD17B10SMN1; SMN2 | |
| SCHEMBL21484237 | 0.93 | GLS (0.68) | GLSALDH1A1CA2HSD17B10SMN1; SMN2 | |
| SCHEMBL14987278 | 0.90 | GLS (0.72) | GLSALDH1A1 | |
| SCHEMBL16384868 | 0.85 | GLS (0.78) | GLSALDH1A1CA2 | |
| SCHEMBL21368592 | 0.84 | GLS (0.53) | GLSALDH1A1HSD17B10 | |
| SCHEMBL14987001 | 0.83 | GLS (0.89) | GLSALDH1A1CA2HSD17B10SMN1; SMN2 | |
| SCHEMBL15727744 | 0.83 | GLS (0.89) | GLSALDH1A1CA2HSD17B10SMN1; SMN2 | |
| SCHEMBL14987262 | 0.83 | GLS (0.82) | GLSALDH1A1CA2 | |
| SCHEMBL14986949 | 0.81 | GLS (1.00) | GLSALDH1A1CA2 | |
| SCHEMBL19920149 | 0.78 | GLS (0.56) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 263/4885CA2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.